bluuebunny/crossref_metadata_2025_split huggingface dataset:
627 INTRACAVITARY CORONARY ARTERIES: IS IT REALLY A RARE FINDING? A CORONARY CT STUDY
Authors: La Mura Lucia , Fassano Nicolas Jose 
Published: December 2022

Abstract

Background
The prevalence and clinical relevance of intracavitary coronary arteries coursing within the right ventricle (RV) or right atrial appendix are largely unknown. Only one study has described a prevalence of 17 cases on 31,748 patients (0,054%) by coronary CT angiography.

Purpose
The aim of the study was to assess in a population that underwent coronary CT (CCT) study, how many intra-chamber courses of coronary artery were observed.

Methods
All patients underwent a CCT study from April 2021 to August 2022 in a single center were enrolled. The CCT was performed by a 128-slices system and analyzed by a single operator with over 3 years of experience.

Results
out of 807 patients (41% female, 61.4±10.2 years) who underwent a CCT study, 14 patients with an intra-chamber coronary course were observed, with a prevalence of 1,73%. In particular, 11 had an intra-right ventricle course of the left anterior descending artery and 3 patients had the right coronary artery coursing within the right atrial appendix.

Conclusions
the intra-chamber course of coronary artery seems to be much more frequent than described in the scientific literature. The intra-right ventricle course of the left anterior descending artery may be the most frequently encountered anomaly.
104 EFFECTIVENESS OF 2014 ESC HCM RISK-SCD SCORE IN PREDICTION OF APPROPRIATE ICD SHOCK
Authors: Buongiorno Antonia Luisa , Blandino Alessandro , Bianchi Francesca , Masi Andrea Sibona , Mabritto Barbara , Luceri Stefania , Bongioanni Sergio , De Rosa Catia , Parrini Iris , Tommasello Antonino , Grossi Stefano , Musumeci Giuseppe 
Published: December 2022

Abstract

Background
Since 2014, European Guidelines have recommended using a novel clinical risk prediction model, called the HCM Risk-SCD, to identify which patients with hypertrophic cardiomyopathy (HCM) who are at higher risk for sudden cardiac death (SCD) and would benefit most from having a prophylactic cardioverter defibrillator (ICD) implantable. In recent years, evidence has called into question the effectiveness of this model in patient selection.

Material and Methods
Data from consecutive patients with HCM and ICD who were followed at our Cardiology Department from January 2000 to January 2022 were retrospectively collected.

Results
Among 702 HCM patients, 52 (7%) received an ICD (female, 31%; mean age at implantation, 49 ± 20; S-ICD, 13%; single-chamber ICD, 50%). Of them, 7 (13%) patients were implanted for secondary prevention while 45 (87%) for primary prevention. Out of the 45 primary prevention patients, 7 (16%) experienced 8 appropriate shocks (AS) while 10 (22%) had 15 inappropriate shocks (IS), during a mean follow up of 8 ± 5 years. Overall, mean HCM Risk-SCD score was 6.8 ± 4.7. Patients with AS showed a non-significant higher risk score when compared to non-AS subjects (7.1 ± 5.4 vs 4.8 ± 5.1, p=0.27). By stratifying study population according to pre-established and clinically adopted HCM Risk-SCD score cut-off (such as &lt; 4 vs. &gt; or = 4), we failed to highlight any significant difference in term of AS between groups. Indeed, out of 10 (22%) patients with HCM Risk-SCD score &lt; 4, 3 (7%) experienced AS, while among 35 (78%) patients with HCM Risk-SCD score &gt; or = 4, 4 (9%) had AS (30% vs. 11%, p=0.17).

Conclusions
The HCM Risk-SCD score does not seem to be able to predict the occurrence of life-threatening ventricular arrhythmias and AS in HCM patients. Our data highlight the need to elaborate a new score in order to improve SCD risk stratification and better select patients for ICD implantation.
4 METABOLIC SYNDROME, HYPERTENSION AND DEPRESSION: A DANGEROUS ASSOCIATION FOR POSTMENOPAUSAL WOMEN
Authors: Maiello Maria , Cecere Annagrazia , Ciccone Marco Matteo , Palmiero Pasquale 
Published: December 2022

Abstract

Background
Depression(D) is a common condition in postmenopausal women, related to an increased risk of cardiovascular disease(CVD), however, the relationship between metabolic syndrome(MetS) and D needs to be better clarified, the same for the association between hypertension(H) and D. The diagnosis of D is yet a challenging problem in clinical practice, there is a wide underdiagnosis of this condition, so the evidence that a Dwell-identified population of postmenopausal women, affected by MetS, presents a high risk, of D occurrence, is useful for CVD prevention. Our study aims to assess the prevalence of metabolic syndrome or hypertension diagnosed according to current guidelines, in postmenopausal women with D, and its role as an independent risk factor.

Results
D rate was significantly higher among women affected by MetS:0.17%, 18 women, than CG:0.08%, 45 women, Chi-squared 9.8, Odds ratio 2.3, c.i.95%, p&lt;0.0017. D rate was significantly higher among women affected by H:0.17%, 107 women, than CG:0.08%, 45 women, Chi-squared 25.9, Odds ratio 2.4, c.i.95%, p&lt;0.0000.
D rate was significantly higher among women affected by metabolic cardiopathy:0.18%, 10 women, than CG:0.08%, 45 women, Chi-squared 5.9, Odds ratio 2.3, c.i.95%, p&lt;0.0014. D rate was significantly higher among women affected by hypertensive cardiopathy:0.12%, 43 women than CG:0.08%, 45 women, Chi-squared 25.9, Odds ratio 2.4, c.i.95%, p&lt;0.05.

Conclusion
There was a wide lack of diagnosis of D in our population because in controlled trials the prevalence of depression is 10-15%. However, we observed an interesting relationship between MetS and D, which is even tighter when restricted to women affected by H; otherwise, the relationship doesn't change when restricted to women affected by metabolic or hypertensive cardiomyopathy. An intervention is needed to improve the diagnosis of D in postmenopausal women, even more, when affected by MetS or D.
Key words: postmenopausal women, metabolic syndrome, hypertension, depression, cardiomyopathy
Long-term risk of new-onset arrhythmia in ST-segment elevation myocardial infarction according to revascularization status
Authors: Thomsen Anna F , Jøns Christian , Jabbari Reza , Jacobsen Mia R , Stampe Niels Kjær , Butt Jawad H , Olsen Niels Thue , Kelbæk Henning , Torp-Pedersen Christian , Fosbøl Emil L , Pedersen Frants , Køber Lars , Engstrøm Thomas , Jacobsen Peter Karl 
Published: December 2022

AbstractAimsEmerging data show that complete revascularization (CR) reduces cardiovascular death and recurrent myocardial infarction in ST-segment elevation myocardial infarction (STEMI). However, the influence of revascularization status on development of arrhythmia in the long-term post-STEMI phase is poorly described. We hypothesized that incomplete revascularization (ICR) compared with CR in STEMI is associated with an increased long-term risk of new-onset arrhythmia.Methods and resultsPatients with STEMI treated with primary percutaneous coronary intervention (PPCI) at Copenhagen University Hospital, Rigshospitalet, Denmark, with CR or ICR were identified via the Eastern Danish Heart registry from 2009 to 2016. Using unique Danish administrative registries, the outcomes were assessed. The primary outcome was new-onset arrhythmia defined as a composite of atrial fibrillation/flutter (AF), sinoatrial block, advanced second- or third-degree atrioventricular block, ventricular tachycardia/fibrillation (VT), or cardiac arrest (CA), with presentation &gt;7 days post-PPCI. Secondary outcomes were the components of the primary outcome and all-cause mortality. A total of 5103 patients (median age: 62.0 years; 76% men) were included, of whom 4009 (79%) and 1094 (21%) patients underwent CR and ICR, respectively. Compared with CR, ICR was associated with a higher risk of new-onset arrhythmia [hazard ratio (HR), 1.33; 95% confidence interval (CI), 1.07–1.66; P = 0.01], AF (HR, 1.29; 95% CI, 1.00–1.66; P = 0.05), a combined outcome of VT and CA (HR, 1.77; 95% CI, 1.10–2.84; P = 0.02) and all-cause mortality (HR, 1.27; 95% CI, 1.05–1.53; P = 0.01). All HRs adjusted.ConclusionAmong patients with STEMI, ICR was associated with an increased long-term risk of new-onset arrhythmia and all-cause mortality compared with CR.
Similar mutation rates but different mutation spectra in moderate and extremely halophilic archaea
Authors: Kucukyildirim Sibel , Ozdemirel Huseyin Ozgur , Lynch Michael 
Published: December 2022

Abstract
Archaea are a major part of Earth’s microbiota and extremely diverse. Yet, we know very little about the process of mutation that drives such diversification. To expand beyond previous work with the moderate halophilic archaeal species Haloferax volcanii, we performed a mutation-accumulation experiment followed by whole-genome sequencing in the extremely halophilic archaeon Halobacterium salinarum. Although Hfx. volcanii and Hbt. salinarum have different salt requirements, both species have highly polyploid genomes and similar GC content. We accumulated mutations for an average of 1250 generations in 67 mutation accumulation lines of Hbt. salinarum, and revealed 84 single-base substitutions and 10 insertion-deletion mutations. The estimated base-substitution mutation rate of 3.99 × 10−10 per site per generation or 1.0 × 10−3 per genome per generation in Hbt. salinarum is similar to that reported for Hfx. volcanii (1.2 × 10−3 per genome per generation), but the genome-wide insertion-deletion rate and spectrum of mutations are somewhat dissimilar in these archaeal species. The spectra of spontaneous mutations were AT biased in both archaea, but they differed in significant ways that may be related to differences in the fidelity of DNA replication/repair mechanisms or a simple result of the different salt concentrations.
Risk factors and clinical outcomes of incomplete endoscopic resection of small rectal neuroendocrine tumors in southern China: a 9-year data analysis
Authors: Zhuang Xiaoduan , Zhang Shaoheng , Chen Guiquan , Luo Zongqi , Hu Huiqin , Huang Wenfeng , Guo Yu , Ouyang Yongwen , Peng Liang , Qing Qing , Chen Huiting , Li Bingsheng , Chen Jie , Wang Xinying 
Published: December 2022

Abstract

Background
The histologically complete resection (CR) rate of small rectal neuroendocrine tumors (RNETs) is unsatisfactory at the first endoscopy. Risk factors and clinical outcomes associated with incomplete resection (IR) have not been explicitly elucidated. This study aims to explore the relevant factors of IR.

Methods
This retrospective study reviewed patients with small RNETs (≤10 mm) in eight centers from January 2013 to December 2021. Clinicopathological characteristics and clinical outcomes were compared between the CR and IR groups, and the polypectomy and advanced treatment groups.

Results
Of the 326 patients included, 83 (25.5%) were diagnosed with IR. Polypectomy (odds ratio [OR] = 16.86), a central depression (OR = 7.50), and treatment in the early period (OR = 2.60) were closely associated with IR. Further analysis revealed that an atypical hyperemic appearance (OR = 7.49) and treatment in the early period (OR = 2.54) were significantly associated with the inappropriate use of polypectomy (both P &lt; 0.05). In addition, a total of 265 (81.3%) were followed up with a median follow-up period of 30.9 months. No death, metastasis, or recurrence was found during the follow-up period.

Conclusions
Polypectomy, a central depression, and treatment in the early period were risk factors for IR. Further, an atypical hyperemic appearance and treatment in the early period were significant predisposing factors for inappropriate choice of polypectomy. For histologically incompletely resected small RNETs, follow-up may be a safe and feasible alternative to rigorous salvage therapy.
Semigroup *-Algebras Arising from Graphs of Monoids
Authors: Chen Cheng , Li Xin 
Published: December 2022

Abstract
We study groupoids and semigroup $C^{\ast }$-algebras arising from graphs of monoids, in the setting of right LCM monoids. First, we establish a general criterion when a graph of monoids gives rise to a submonoid of the fundamental group that is right LCM. Moreover, we carry out a detailed analysis of structural properties of semigroup $C^{\ast }$-algebras arising from graphs of monoids, including closed invariant subspaces and topological freeness of the groupoids, as well as ideal structure, nuclearity, and K-theory of the semigroup $C^{\ast }$-algebras. As an application, we construct families of pairwise nonconjugate Cartan subalgebras in every UCT Kirchberg algebra.
Presenting Lusztig Algebras
Authors: Fu Qiang , Liu Mingqiang 
Published: December 2022

Abstract
Let ${\textbf {U}}_{\!\vartriangle }(n)$ be the quantized enveloping algebra of $\widehat {\mathfrak {g}\mathfrak {l}}_n^{\prime}$ over ${\mathbb {Q}}(v)$, where $\widehat {\mathfrak {g}\mathfrak {l}}_n^{\prime}=\mathfrak {g}\mathfrak {l}_n\oplus \bigoplus _{l\in {\mathbb {Z}},\,l\not =0}{\scriptsize{\rm t}}^l\mathfrak {s}\mathfrak {l}_n$. There is a natural algebra homomorphism $\zeta _r$ from ${\textbf {U}}_{\!\vartriangle }(n)$ to the affine quantum Schur algebra ${\boldsymbol {{\mathcal {S}}}}_{\!\vartriangle }(n,r)$. Let $ U_{\!\vartriangle }(n)_{{{\mathcal {Z}}}}$ be the Lusztig ${{\mathcal {Z}}}$-form of ${\textbf {U}}_{\!\vartriangle }(n)$, where ${{\mathcal {Z}}}={\mathbb {Z}}[v,v^{-1}]$. The algebras ${\textbf {U}}_{\!\vartriangle }(n,r):=\zeta _r({\textbf {U}}_{\!\vartriangle }(n))$ and $U_{\!\vartriangle }(n,r)_{{\mathcal {Z}}}:=\zeta _r( U_{\!\vartriangle }(n)_{{{\mathcal {Z}}}})$ are called Lusztig algebras. Let $\mathcal {K}$ be a commutative ring containing an invertible element $\epsilon $. Let $U_{\!\vartriangle }(n,r)_{\mathcal {K}}=U_{\!\vartriangle }(n,r)_{{\mathcal {Z}}}\otimes _{{\mathcal {Z}}}\mathcal {K}$, where $\mathcal {K}$ is regarded as a ${{\mathcal {Z}}}$-module by specializing $v$ to $\epsilon $. In this paper, we give a presentation for the Lusztig algebra $U_{\!\vartriangle }(n,r)_{\mathcal {K}}$ for any commutative ring $\mathcal {K}$.
Critically Appraising Pragmatist Critiques of Evidence-Based Medicine: Is EBM Defensible on Pragmatist Grounds?
Authors: Thomas S Joshua 
Published: December 2022

AbstractSignificant contributions to debates in the philosophy of evidence-based medicine (EBM) have come from a variety of different philosophical quarters, yet mainstream discourse in the field has been largely devoid of contributions from scholars working in the pragmatist tradition. This is a particularly conspicuous omission, given pragmatism’s commitment to the melioristic view that philosophy both can, and should, be about the business of concretely bettering the human estate. Two exceptions to this oversight come from Brian Walsh and Maya Goldenberg. Unfortunately, in both cases, the misapplication of pragmatist thinking leads to the mistaken view that EBM is committed to some form of pernicious objectivism. This article aims to revise these pragmatist critiques in order to bring them more consistently in line with pragmatist values and commitments. Doing so shows that EBM is defensible on pragmatist grounds against objectivist attacks.
Enrolling Older Adults Onto National Cancer Institute–Funded Clinical Trials in Community Oncology Clinics: Barriers and Solutions
Authors: Hopkins Judith O , Braun-Inglis Christa , Guidice Sofia , Wells Meg , Moorthi Kiran , Berenberg Jeffrey , St. Germain Diane , Mohile Supriya , Hudson Matthew F 
Published: December 2022

Abstract
In April 2021, the National Cancer Institute (NCI) Division of Cancer Prevention collaborated with the NCI Division of Cancer Treatment and Diagnosis to produce a virtual workshop that developed recommendations for enhancing NCI-sponsored clinical trial accrual of older adults. Prior to the workshop, a multidisciplinary group of stakeholders (eg, community oncologists, advanced practice practitioners, clinic and research staff, and patient advocates) gathered information related to accrual of older adults to clinical trials from the literature. Subsequently, a survey was conducted to detail NCI Community Oncology Research Program members’ perspective on accrual barriers for this population; 305 individuals responded to the survey. Barriers to clinical trial accruals included comorbidity-attributed trial ineligibility, transportation and time issues, concern that the proposed regimen is too toxic for older adults, patient or family caregiver declined participation, and lack of trials relevant to older patients. Identified solutions included broadening clinical trial inclusion criteria, increasing the number of clinical trials specifically designed for older adults, simplifying consent forms, improving recruitment materials for older adults and their families, and facilitating transportation vouchers. At the workshop, participants, including stakeholders, used prior literature and survey results to develop recommendations, including interventions to address clinician bias, implement geriatric assessment, and promote clinician and staff engagement as mechanisms to improve accrual of older adults to clinical trials.
Through the Lens of Patient Partners: Challenges in Accrual of Older Adults to NCI Clinical Trials
Authors: BrintzenhofeSzoc Karlynn , Canin Beverly , Casas-Silva Esmeralda , Denicoff Andrea , Braun-Inglis Christa , Okado Izumi , Bakos Alexis 
Published: December 2022

AbstractThe workshop “Engaging Older Adults in Cancer Clinical Trials Conducted in the NCI Clinical Trials Network: Challenges and Opportunities” included a Patient Stakeholder Workgroup that explored the needs and concerns of older adults with cancer regarding clinical trials. To accomplish this, the workgroup conducted patient focus groups in which participants were interviewed, recorded conversations were analyzed and coded, and salient themes were identified. The focus groups identified general barriers to accrual such as complex consent forms, general communication, restrictive eligibility, nonreferrals, patient costs, cultural insensitivity, limited accessibility in community settings, and transportation issues. They also identified the influence of knowledgeable information presenters, improved care, family or caregiver support, and the desire to help others as drivers or reasons to participate in clinical trials. The workshop concluded that multi-level interventions could be used to increase the accrual of older adults to National Cancer Institute clinical trials as well as others.
Infrastructure to Support Accrual of Older Adults to National Cancer Institute Clinical Trials
Authors: Kimmick Gretchen , Sedrak Mina S , Williams Grant , McCleary Nadine J , Rosko Ashley E , Berenberg Jeffrey L , Freedman Rachel A , Smith Mary Lou , Ahmed Amina , Muss Hyman B , Chow Selina , Dale William 
Published: December 2022

AbstractAs part of ongoing efforts to meaningfully improve recruitment, enrollment, and accrual of older adults into cancer clinical trials, the National Cancer Institute (NCI) sponsored a workshop with experts across the country entitled Engaging Older Adults in the NCI Clinical Trials Network: Challenges and Opportunities. Three working groups, including Study Design, Infrastructure, and Stakeholders, were formed, who worked together to offer synergistic improvements in the system. Here, we summarize the workshop discussions of the Infrastructure Working Group, whose goal was to address infrastructural challenges, identify underlying resources, and offer solutions to facilitate accrual of older adults into cancer clinical trials. Based on preconference work and workshop discussions, four key recommendations to strengthen NCI infrastructure were proposed: 1) further centralize resources and expertise; 2) provide training for clinical research staff; (3) develop common data elements; and 4) evaluate what works and does not work. These recommendations provide a strategy to improve the infrastructure to enroll more older adults in cancer clinical trials.
736. Impact of COVID-19 on Mortality Associated with Pseudomonas aeruginosa Bloodstream Infection in the Veterans Health Administration System
Authors: Hojat Leila S , Wilson Brigid , Perez Federico , Bonomo Robert A 
Published: December 2022

Abstract

Background
Pseudomonas aeruginosa bloodstream infection (PA-BSI) is associated with high mortality. The extent to which the COVID-19 pandemic has introduced challenges to diagnosis and treatment of this infection is unknown. In this study, we examined the direct and indirect effects of COVID-19 on PA-BSI associated mortality in the Veterans Health Administration (VHA) population.

Methods
We identified patients within the VHA database with PA-BSI identified between January 1, 2009 and December 31, 2019 (pre-COVID) and January 1, 2020 to December 31, 2021 (COVID). Extracted data included age, race, ethnicity, Charlson Comorbidity Index (CCI), susceptibility testing, treatment, and COVID-19 infection. Antimicrobial resistance was characterized as pan-susceptible, any unclassified resistance, multi-drug resistant (MDR), difficult to treat resistant (DTR), and extremely or pan-drug resistant (XDR/PDR). Active therapy was defined as an effective antibiotic initiated within 48 hours of blood culture collection. We used logistic regression to assess the impact of each factor on 30-day mortality.

Results
We identified 7,578 patients with PA-BSI and known 30-day mortality status, which was 24% overall (Table 1). Age and CCI were higher during COVID, while effective treatment and resistance improved (Table 2). In the multivariate analysis, concomitant COVID infection tripled the odds of mortality (odds ratio [OR] 3.00, 95% confidence interval [CI] 1.40–6.37) (Figure 1). However, the COVID period itself was not associated with higher mortality. Effective treatment was associated with 19% lower odds of mortality (OR 0.81, 95% CI 0.66–1.01), while DTR and XDR/PDR nearly doubled mortality (OR 1.75, 95% CI 1.23–2.47 and OR 2.06, 95% CI 1.25–3.34, respectively).

Conclusion
We observed higher odds of mortality in patients with PA-BSI and COVID-19 coinfection, supporting the hypothesis that COVID-19 directly impacts PA-BSI outcomes. Annual PA-BSI incidence and associated 30-day mortality, however, were similar during the COVID period. Favorable resistance trends, effective treatment, and a low rate of PA-BSI and COVID-19 coinfection may explain these findings, despite increased age and comorbidities in this vulnerable population.

Disclosures
Federico Perez, MD, MS, Accelerate: Grant/Research Support|Merck: Grant/Research Support|Pfizer: Grant/Research Support Robert A. Bonomo, MD, Merck: Grant/Research Support|Pfizer: Honoraria|VenatoRx: Grant/Research Support|Wockhardt: Grant/Research Support.